1. Generics Bulletin
  2. >>Leadership

Who’s Hired? Lupin Appoints CEO To New API CDMO Subsidiary

ChemWerth’s CEO And President Passes On Reins To His Son

 
• By Urtė Fultinavičiūtė

Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.

Concept of hiring people
• Source: Shutterstock

Indian generics firm Lupin has accomplished two things at once – announced a freshly formed subsidiary Lupin Manufacturing Solutions and appointed a CEO to lead the new business venture.

Abdelaziz Toumi brings over two decades of experience in the biotech, pharma, and contract development and manufacturing operations sectors, spanning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By Aakash Babu

Joshi joins the parent company of Citeline, which houses flagship publications Generics Bulletin, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By Dave Wallace

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By Dave Wallace

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By Dave Wallace

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.

More from Generics Bulletin